An image of a smartphone and a pen
Markets

Weekly CFO Buys Highlight: BioDelivery Sciences International, TheStreet, Antares Pharma

According to GuruFocus Insider Data, the recent CFO buys were: BioDelivery Sciences International Inc. ( BDSI ), TheStreet Inc. ( TST ) and Antares Pharma Inc. ( ATRS ).

BioDelivery Sciences International Inc. ( BDSI ): CFO, Secretary and Treasurer Ernest Robert De Paolantonio bought 4,000 shares

On March 17, Paolantonio bought 4,000 shares at an average price of $2.6. The price of the stock has increased by 14.23%. Biodelivery Sciences International Inc. has a market cap of $158.8 million and its shares were traded around $2.97. The company has a P/S ratio of 3.23.

BioDelivery Sciences International Inc. announced its 2015 fourth quarter results with revenues of $32.21 million and gross profit of $29.55 million, while the net income was $10.17 million. The 2015 total revenue was $48.23 million, a 24% increase from the 2014 total revenue. The 2015 gross profit was $40.13 million, an 18% increase from the 2014 gross profit. The 2015 net loss was $37.67 million.

On March 21, Director Charles Bramlage bought 8,850 shares at an average price of $2.82. The price of the stock has increased by 5.32%. On March 18, Chief Technology Officer Niraj Vasisht bought 1,000 shares at an average price of $2.8. The price of the stock has increased by 6.07%. On March 18, Director Barry Feinberg bought 10,000 shares at an average price of $2.74. The price of the stock has increased by 8.39%.

TheStreet Inc. ( TST ): CFO Eric F Lundberg bought 6,598 shares

On Mar. 21, Lundberg bought 6,598 shares at an average price of $1.2. The price of the stock has increased by 2.5%. TheStreet Inc. has a market cap of $43.33 million and its shares were traded around $1.23. The company has a P/S ratio of 0.63. The trailing 12-month dividend yield of the stock is 8.13%, while the forward dividend yield is 8.13%.

TheStreet announced its 2015 fourth quarter results with revenues of $16.97 million and gross profit of $8.97 million, while the net loss was $249,000. The 2015 total revenue was $67.66 million, an 11% increase from the 2014 total revenue. The 2015 gross profit was $34.04 million, a 16% increase from the 2014 gross profit. The 2015 net loss was $1.54 million.

On Nov. 11, CEO Elisabeth H Demarse bought 40,000 shares at an average price of $1.63. The price of the stock has decreased by 24.54%. On March 23, Director Lawrence S Kramer bought 42,013 shares at an average price of $1.19. The price of the stock has increased by 3.36%. On March 14, Director Stephen Zacharias bought 40,000 shares at an average price of $1.12. The price of the stock has increased by 9.82%.

Antares Pharma Inc. ( ATRS ): Senior Vice President and CFO James E Fickenscher bought 135,000 shares

On March 18, Fickenscher bought 135,000 shares at an average price of $0.72. Antares Pharma Inc. has a market cap of $110.380 million and its shares were traded around 71 cents. The company has a P/S ratio of 2.29. Over the past five years, Antares Pharma Inc. had an annual average earnings

M 15-Year Financial Data

The intrinsic value of M

Peter Lynch Chart of M

Warning! GuruFocus has detected 4 Warning Sign with TSM. Click here to check it out.

TSM 15-Year Financial Data

The intrinsic value of TSM

Peter Lynch Chart of TSM

Warning! GuruFocus has detected 3 Warning Signs with LEN. Click here to check it out.

LEN 15-Year Financial Data

The intrinsic value of LEN

Peter Lynch Chart of LEN

Warning! GuruFocus has detected 5 Warning Signs with BDSI. Click here to check it out.

BDSI 15-Year Financial Data

The intrinsic value of BDSI

Peter Lynch Chart of BDSI

Read More:

About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .

This article first appeared on GuruFocus .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ATRS BDSI

Other Topics

Stocks

Latest Markets Videos